Chemotherapy of human African trypanosomiasis: current and future prospects (Q35569065)

8 August 2017

1 reference

title

Chemotherapy of human African trypanosomiasis: current and future prospects (English)

1 reference

8 August 2017

0 references

African trypanosomiasis

0 references

1 reference

Alan H Fairlamb

1

0 references

language of work or name

English

1 reference

National Center for Biotechnology Information

PubMed ID

14580959

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14580959

25 March 2024

publication date

1 November 2003

1 reference

PubMed ID

14580959

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S1471492203002423?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

https://api.elsevier.com/content/article/PII:S1471492203002423?httpAccept=text/plain

25 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

25 March 2024

published in

Trends in Parasitology

1 reference

8 August 2017

19

1 reference

8 August 2017

488-494

1 reference

8 August 2017

11

1 reference

Access to essential drugs in poor countries: a lost battle?

8 August 2017

1

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Resurrecting the resurrection drug

25 March 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

The treatment of human African trypanosomiasis

25 March 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

25 March 2024

antiprotozoal

4

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Suramin's development: what did we learn?

25 March 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Uptake of the trypanocidal drug suramin by bloodstream forms of Trypanosoma brucei and its effect on respiration and growth rate in vivo

25 March 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action

25 March 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Evidence for a non-LDL-mediated entry route for the trypanocidal drug suramin in Trypanosoma brucei

25 March 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin

25 March 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei

25 March 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs

25 March 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Inhibition of Trypanosoma brucei gene expression by RNA interference using an integratable vector with opposing T7 promoters

25 March 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Pentamidine inhibits catalytic activity of group I intron Ca.LSU by altering RNA folding.

25 March 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Inhibition of in vitro splicing of a group I intron of Pneumocystis carinii

25 March 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Polyamine and pentamidine metabolism in African trypanosomes

25 March 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

S-adenosylmethionine decarboxylase from Leishmania donovani. Molecular, genetic, and biochemical characterization of null mutants and overproducers

25 March 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

A calmodulin-stimulated Ca2+ pump in plasma-membrane vesicles from Trypanosoma brucei; selective inhibition by pentamidine

25 March 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Ca2+ transport by digitonin-permeabilized Leishmania donovani. Effects of Ca2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ

25 March 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Surface receptors and transporters of Trypanosoma brucei

25 March 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes

25 March 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Pentamidine uptake and resistance in pathogenic protozoa: past, present and future

25 March 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Arsenical-resistant trypanosomes lack an unusual adenosine transporter

25 March 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Uptake of pentamidine in Trypanosoma brucei brucei is mediated by the P2 adenosine transporter and at least one novel, unrelated transporter

25 March 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Characterisation of pentamidine-resistant Trypanosoma brucei brucei

25 March 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Pharmacokinetic properties of the trypanocidal drug melarsoprol

25 March 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial

25 March 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia.

25 March 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Investigations of the metabolites of the trypanocidal drug melarsoprol

25 March 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Effects of various metabolic conditions and of the trivalent arsenical melarsen oxide on the intracellular levels of fructose 2,6-bisphosphate and of glycolytic intermediates in Trypanosoma brucei.

25 March 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Trypanothione is the primary target for arsenical drugs against African trypanosomes

25 March 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Metabolism and functions of trypanothione in the Kinetoplastida

25 March 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei

25 March 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress

25 March 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Polyamine biosynthetic enzymes as drug targets in parasitic protozoa

25 March 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Combination chemotherapy of CNS trypanosomiasis

25 March 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis

25 March 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Relationship of global chloroquine transport and reversal of resistance in Plasmodium falciparum.

25 March 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Sensitivity of parasites to free radical damage by antiparasitic drugs

25 March 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Trypanosoma rhodesiense: evaluation of the antitrypanosomal action of 2,5-bis(4-guanylphenyl)furan dihydrochloride

25 March 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

New drugs for the treatment of human African trypanosomiasis: research and development

25 March 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Chemotherapy of human African trypanosomiasis

25 March 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development

25 March 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents

25 March 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

TbMP81 is required for RNA editing in Trypanosoma brucei

25 March 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies

25 March 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Glucose is toxic to glycosome-deficient trypanosomes.

25 March 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Galactose metabolism is essential for the African sleeping sickness parasite Trypanosoma brucei

25 March 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Recent advances in identifying and validating drug targets in trypanosomes and leishmanias.

25 March 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Cysteine protease inhibitors as chemotherapy for parasitic infections

25 March 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Computational methods for the prediction of 'drug-likeness'

25 March 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

Recognizing molecules with drug-like properties

25 March 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.PT.2003.09.002

25 March 2024

Identifiers

1 reference

8 August 2017

1 reference

PubMed ID

14580959